Kevin Rodondi, PharmD
Professor Emeritus
Clinical Pharmacy
School of Pharmacy

Education & Training

Show all (2) Hide

• PHA Primary Practice Residency Pharmacy University of California, San Francisco 1986
• Pharm.D. Pharmacy University of California, San Francisco 1985

Websites

Show all (5) Hide

• Healthforce Center at UCSF (healthforce.ucsf.edu)
• HITIDE (hitide.research.hawaii.edu)
• Posts on X kevinrodondi (X.com)
• NSF Convergence Accelerator (beta.nsf.gov)
• NIH I-Corp (sbir.cancer.gov)

Publications (3)

Top publication keywords:
DoxorubicinCost-Benefit AnalysisAcademic Medical CentersMedical OncologyQualitative ResearchReproducibility of ResultsDrug-Related Side Effects and Adverse ReactionsDrug PackagingFocus GroupsPatient-Centered CareDrug LabelingPharmacistsDrug CostsAntineoplastic AgentsNeoplasms

• What Is a Medication-Related Problem? A Qualitative Study of Older Adults and Primary Care Clinicians.
  Journal of general internal medicine 2019 Nicosia FM, Spar MJ, Stebbins M, Sudore RL, Ritchie CS, Lee KP, Rodondi K, Steinman MA
• Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
  Journal of managed care & specialty pharmacy 2017 Wilson L, Lin T, Wang L, Patel T, Tran D, Kim S, Dacey K, Yuen C, Kroon L, Brodowy B, Rodondi K
• Doxorubicin multiple-dose vials.
  American journal of hospital pharmacy 1990 Rodondi KM